Stem Cell Theranostics and CapellaBio Announce Cardio-Oncology Collaboration and Discovery of a Novel Class of Cardioprotective Drug Therapies
Admin • CCON • 12/16/2015
REDWOOD CITY, Calif. and PALO ALTO, Calif., Dec. 16, 2015 /PRNewswire/ — Stem Cell Theranostics (SCT) and CapellaBio announced today that they have established a cardio-oncology collaboration to discover novel drug therapies to prevent cardiotoxicity associated with various oncology drugs. By combining CapellaBio’s SMarTR computational analysis platform with SCT’s iPSC-derived cardiomyocyte discovery platform, advanced drug leads have been identified in the first of a series of programs.
SOURCE Stem Cell Theranostics Inc